Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dust mite mixture** is a sublingual allergen immunotherapy preparation comprising allergenic material from *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus* with a pharmaceutically acceptable carrier. Repeated controlled sublingual exposure is intended to induce allergen-specific immune tolerance and reduce IgE-mediated respiratory-allergy symptoms. The exact Chinese name, 尘螨合剂, is described in a Chinese patent for treatment of allergic diseases and was evaluated in the registered multicenter, randomized, double-blind, placebo-controlled ChiCTR-IIR-17013839 study for allergic rhinitis, with allergic asthma also represented in the trial context. ([europepmc.org](https://europepmc.org/patents/PAT/CN1840189))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dust mite mixture (Wolwo Biotech).